The pharmacokinetics of epirubicin was studied in patients with soft tissue sarcomas or advanced breast cancer. The epirubicin was given as an i.v. bolus injection of 75 or 90 mg/m2. Blood and urine samples were collected at regular time intervals for at least 48 hours. Extraction and high performance liquid chromatography of the samples were done. It was found that epirubicin compared to doxorubicin has a unique glucuronidation pathway which may explain its shorter half-life and its reduced cardiotoxicity.
|Original language||English (US)|
|Number of pages||5|
|Journal||Clinical Trials Journal|
|Issue number||SUPPL. 1|
|State||Published - 1987|
ASJC Scopus subject areas
- Pharmacology (medical)